REG - Proteome Sciences - Completion of new facility in San Diego

Proteome SciencesAnnouncement

02/01/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240102:nRSB2683Ya&default-theme=true

RNS Number : 2683Y  Proteome Sciences PLC  02 January 2024

2 January 2024

 

 

Proteome Sciences plc

("Proteome Sciences" or the "Company")

 

Completion of new facility in San Diego

 

Proteome Sciences is pleased to announce the completion of installation and
setup of equipment in its new US laboratory in San Diego, California. and is
therefore now fully operational. The laboratory uses the latest generation
Orbitrap Ascend Tribrid mass spectrometry and automated sample preparation
platforms that will extend the range of services offered to customers.

 

This new facility is based in one of the largest biotech hubs in the US - a
hub which has had, collectively, investment of $17.2 bn and US National
Institute of Health funding of $6bn in 2022/23 - Proteome Sciences' state of
the art Laboratory is well placed to serve demand from a growing number of US
customers looking to outsource proteomics projects to underpin their drug
development programmes. By removing the need to ship samples internationally
our services are more attractive to customers from both Pharma and academia
alike.

 

Dr. Ian Pike, President of Proteome Sciences US Inc, commented "I am delighted
that we are able to open our doors to serve arguably the world's largest
biotechnology hub in California. Providing easier access to our US customers
and with innovations including TMTpro 32plex and single cell proteomics (SCP),
delivered from both our dedicated laboratories in the US and Europe we are
well set to continue our leading role in provision of tools, assays and
services in proteomics research as it grows in importance to enhance
pharmaceutical research and drug development."

 

 

For further information:

 Proteome Sciences plc
 Dr. Mariola Soehngen, Chief Executive Officer                           Tel: +44 (0)20 7043 2116

 Dr. Ian Pike, Chief Scientific Officer
 Richard Dennis, Chief Commercial Officer

 Abdelghani Omari, Chief Financial Officer

 Allenby Capital Limited (Nominated Adviser & Broker)
 John Depasquale / Jeremy Porter (Corporate Finance)                     Tel: +44 (0) 20 3328 5656

 Tony Quirke / Stefano Aquilino (Equity Sales & Corporate Broking)

 

About Proteome Sciences plc. (www.proteomics.com (http://www.proteomics.com/)
)

 

Proteome Sciences plc is a specialist provider of contract proteomics services
to enable drug discovery, development and biomarker identification, and
employs proprietary workflows for the optimum analysis of tissues, cells and
body fluids. SysQuant® and TMT®MS2 are unbiased methods for identifying and
contextualising new targets and defining mechanisms of biological activity,
while analysis using Super-Depletion and TMTcalibrator™ provides access to
over 8,500 circulating plasma proteins for the discovery of disease-related
biomarkers. Targeted assay development using mass spectrometry delivers high
sensitivity, interference-free biomarker analyses in situations where standard
ELISA assays are not available.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDBXBDDUDXDGXB